Alternative mechanisms of miR-34a regulation in cancer

被引:0
|
作者
Eva Slabáková
Zoran Culig
Ján Remšík
Karel Souček
机构
[1] Institute of Biophysics of the Czech Academy of Sciences,Department of Cytokinetics
[2] Center of Biomolecular and Cellular Engineering,Division of Experimental Urology, Department of Urology
[3] International Clinical Research Center,Department of Experimental Biology
[4] St. Anne’s University Hospital Brno,undefined
[5] Medical University of Innsbruck,undefined
[6] Faculty of Science,undefined
[7] Masaryk University,undefined
来源
Cell Death & Disease | 2017年 / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
MicroRNA miR-34a is recognized as a master regulator of tumor suppression. The strategy of miR-34a replacement has been investigated in clinical trials as the first attempt of miRNA application in cancer treatment. However, emerging outcomes promote the re-evaluation of existing knowledge and urge the need for better understanding the complex biological role of miR-34a. The targets of miR-34a encompass numerous regulators of cancer cell proliferation, survival and resistance to therapy. MiR-34a expression is transcriptionally controlled by p53, a crucial tumor suppressor pathway, often disrupted in cancer. Moreover, miR-34a abundance is fine-tuned by context-dependent feedback loops. The function and effects of exogenously delivered or re-expressed miR-34a on the background of defective p53 therefore remain prominent issues in miR-34a based therapy. In this work, we review p53-independent mechanisms regulating the expression of miR-34a. Aside from molecules directly interacting with MIR34A promoter, processes affecting epigenetic regulation and miRNA maturation are discussed. Multiple mechanisms operate in the context of cancer-associated phenomena, such as aberrant oncogene signaling, EMT or inflammation. Since p53-dependent tumor-suppressive mechanisms are disturbed in a substantial proportion of malignancies, we summarize the effects of miR-34a modulation in cell and animal models in the clinically relevant context of disrupted or insufficient p53 function.
引用
收藏
页码:e3100 / e3100
相关论文
共 50 条
  • [31] MiR-34a modulates ErbB2 in breast cancer
    Wang, Yilin
    Zhang, Xiaolong
    Chao, Zou
    Kung, Hsiang-Fu
    Lin, Marie C.
    Dress, Andreas
    Wardle, Fiona
    Jiang, Bing-Hua
    Lai, Lihui
    [J]. CELL BIOLOGY INTERNATIONAL, 2017, 41 (01) : 93 - 101
  • [32] INVOLVEMENT OF MiR-34A IN RESISTANCE OF BREAST CANCER CELLS TO DOCETAXEL
    Kastl, Lena
    Schofield, Andrew C.
    [J]. EJC SUPPLEMENTS, 2010, 8 (06): : 20 - 21
  • [33] A Systemic Review on the Regulatory Roles of miR-34a in Gastrointestinal Cancer
    Kong, Jiehong
    Wang, Weipeng
    [J]. ONCOTARGETS AND THERAPY, 2020, 13 : 2855 - 2872
  • [34] Identification of Key Genes in Colorectal Cancer Regulated by miR-34a
    Wang, Tao
    Xu, Haihe
    Liu, Xianglong
    Chen, Shuo
    Zhou, Yi
    Zhang, Xipeng
    [J]. MEDICAL SCIENCE MONITOR, 2017, 23 : 5735 - 5743
  • [35] Early Targets of miR-34a in Neuroblastoma
    De Antonellis, Pasqualino
    Carotenuto, Marianeve
    Vandenbussche, Jonathan
    De Vita, Gennaro
    Ferrucci, Veronica
    Medaglia, Chiara
    Boffa, Iolanda
    Galiero, Alessandra
    Di Somma, Sarah
    Magliulo, Daniela
    Aiese, Nadia
    Alonzi, Alessandro
    Spano, Daniela
    Liguori, Lucia
    Chiarolla, Cristina
    Verrico, Antonio
    Schulte, Johannes H.
    Mestdagh, Pieter
    Vandesompele, Jo
    Gevaert, Kris
    Zollo, Massimo
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2014, 13 (08) : 2114 - 2131
  • [36] Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression
    Aherne, Sinead T.
    Madden, Stephen F.
    Hughes, David J.
    Pardini, Barbara
    Naccarati, Alessio
    Levy, Miroslav
    Vodicka, Pavel
    Neary, Paul
    Dowling, Paul
    Clynes, Martin
    [J]. BMC CANCER, 2015, 15
  • [37] EARLY TARGETS OF MIR-34A IN NEUROBLASTOMA
    De Antonellis, P.
    Carotenuto, M.
    De Vita, G.
    Vandenbussche, J.
    Medaglia, C.
    Vandesopele, J.
    Mestdagh, P.
    Martens, L.
    An, S.
    Moens, K.
    Cinalli, G.
    Gevaert, K.
    Zollo, M.
    [J]. PEDIATRIC BLOOD & CANCER, 2013, 60 : 116 - 116
  • [38] MiR-34a and p53
    Hermeking, Heiko
    [J]. CELL CYCLE, 2009, 8 (09) : 1308 - 1308
  • [39] Emergence of miR-34a in radiation therapy
    Lacombe, Jerome
    Zenhausern, Frederic
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 109 : 69 - 78
  • [40] Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression
    Sinéad T Aherne
    Stephen F Madden
    David J Hughes
    Barbara Pardini
    Alessio Naccarati
    Miroslav Levy
    Pavel Vodicka
    Paul Neary
    Paul Dowling
    Martin Clynes
    [J]. BMC Cancer, 15